Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors

Medical Oncology

Volumn 25, Issue 2, 2008, Pages 207-213

  Lim, Ken Hong ^a,b   Huang, Ming Jer ^a,c   Chen, Li Tzong ^d,e   Wang, Tsang En ^a,b   Liu, Chien Liang ^a,b   Chang, Cheng Shyong ^f   Liu, Mei Chin ^g   Hsieh, Reuy Kuen ^a   Tzen, Chin Yuan ^a,b,h,i  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^g KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^h NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

ⁱ TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Gastrointestinal stromal tumors; Imatinib; Kinase mutation; KIT; Platelet derived growth factor receptor alpha; Secondary resistance

Indexed keywords

IMATINIB; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEMOGRAPHY; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR BIOPSY; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MORTALITY; MUTATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 48049101758     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-9014-2     Document Type: Article

References (23)

1. S Hirota 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 80
2. MC Heinrich 2003 PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 708 10
3. B Nilsson 2005 Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden Cancer 103 821 9
4. Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005;117:289-93.
5. CY Tzen 2007 Incidence of gastrointestinal stromal tumor: a retrospective study based on immunohistochemical and mutational analyses Dig Dis Sci 52 792 7
6. SC Lin 2003 Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors World J Gastroenterol 9 2809 12
7. GD Demetri 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 80
8. LL Chen 2004 A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors Cancer Res 64 5913 9
9. E Tamborini 2004 A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient Gastroenterology 127 294 9
10. T Wakai 2004 Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation Br J Cancer 90 2059 61
11. CR Antonescu 2005 Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 4182 90
12. M Debiec-Rychter 2005 Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants Gastroenterology 128 270 9
13. Tamborini E, et al. KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient. Cancer Res 2005;65:1115 (author reply 1115).
14. E Wardelmann 2005 Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations Lancet Oncol 6 249 51
15. F Grimpen 2005 Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour Lancet Oncol 6 724 7
16. SR McLean 2005 Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala Mol Cancer Ther 4 2008 15
17. E Wardelmann 2006 Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate Clin Cancer Res 12 1743 9
18. MC Heinrich 2006 Molecular correlates of imatinib resistance in gastrointestinal stromal tumors J Clin Oncol 24 4764 74
19. M Miettinen 2003 Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases Am J Surg Pathol 27 625 41
20. MC Heinrich 2006 Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status J Clin Oncol 24 Suppl 18 9502
21. CL Corless 2005 PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib J Clin Oncol 23 5357 64
22. CL JA Corless Fletcher JA Fletcher MC Heinrich 2004 Biology of gastrointestinal stromal tumors J Clin Oncol 22 3813 25
23. GD Demetri 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329 38